The risk of superinfection following routine abdominal drainage after major surgery is debated. Especially in patients with malignant diseases and a compromised host defense, this might be a factor increasing morbidity and mortality. During a 3-year period (1986)(1987)(1988) 41 patients operated on for malignant abdominal conditions received a peritoneal catheter connected to a subcutaneous portal inserted in order to participate in a trial on postoperative intraperitoneal chemotherapy using 5-Fluorouracil. No abdominal drains were inserted. In 15 patients, the subcutaneous portal was used for evacuation of postoperative fluid accumulation within the abdomen. The mean age was 53 (range years. Inserted catheters were used for drainage up to 1.4 days postoperatively. The daily amount of fluid drained varied from 20 to 2 000 ml with a mean of 610 ml/patient and day. One patient required removal of the catheter due to infection around the subcutaneous chamber. Otherwise, the catheter system was not associated with any other complications or complaints. One patient developed a postoperative left subphrenic abscess drained percutaneously by the guidance of ultrasonography, a complication that could not be attributed to the catheter system but merely to the major operation per se. An implantable device for peritoneal access thus also seem useful for drainage of postoperative fluid collection, as evaluated in this preliminary report.
INTRODUCTION
Prophylactic drainage following major abdominal surgery has previously been routinely used. The benefit of routine drainage following major abdominal surgery has, however, been questioned and drainage as a port of entry for bacteria has been proposed1. In patients with malignant diseases and a compromised host defense against infection, a percutaneous drain carries the risk of introducing bacteria intraabdominally and thereby increasing morbidity and mortality.
Additional methods of treating these abdominal malignancies are sought for. Intraperitoneal chemotherapy through an implantable system for peritoneal access has been under trial during recent years. Probably the most experience hitherto concerns the use of intraperitoneal chemotherapy for ovarian carcinoma, 2-5 though also trials on the value of intraperitoneal 5-Fluorouracil in patients with colorectal liver metastases [6] [7] [8] 
RESULTS
Fifteen out of the total of 41 patients (37%) had the peritoneal access system used for the evacuation of postoperative fluid accumulations. In these cases, the inserted catheters were used for drainage up to 14 days postoperatively. The mean daily amount of drained fluid per patients was 610 ml with a range from 20 to 2 000 ml.
The fluid that was drained was in general clear and uninfected. The subcutaneous portal and catheter system seemed in general to be well tolerated and complications were few. One patient had the catheter removed due to a local infection around the subcutaneous port. One patient developed a subphrenic abscess drained percutaneously with the guidance of ultrasonography, a complication that was not contributed to by the catheter system per se, but merely to the major operation performed.
Among the remaining 26 patients, 3 abdominal abscesses were diagnosed in the postoperative period, 2 managed percutaneously and 1 surgically. No correlation between the use of conventional drainage and abscess formation could be seen in this small series.
DISCUSSION
Intraperitoneal administration of cytostatic agents, for example, using the described system is simple, without a need for an indwelling arterial catheter and infusion pump. The system provides a more uniform delivery to the hepatic parenchyma and it achieves the highest plasma levels in the portal system. It can also be used for treating concomitant intraabdominal disease, which may benefit from intraperitoneal therapy. The exact indications for using this route of administering cytostatic agents, however, remain to be defined.
Implantable ports allow flow rates up to 37 ml/minute with 1 meter of gravity pressure9. This 
